-DOCSTART- -X- O
Background -X- _ O
Allergic -X- _ O
reactions -X- _ O
to -X- _ O
Hymenoptera -X- _ O
insect -X- _ O
stings -X- _ O
remain -X- _ O
a -X- _ O
major -X- _ O
global -X- _ O
clinical -X- _ O
problem. -X- _ O
Although -X- _ O
effective -X- _ O
, -X- _ O
parenteral -X- _ O
desensitization -X- _ O
regimens -X- _ O
require -X- _ O
use -X- _ O
of -X- _ O
costly -X- _ O
venom -X- _ O
extracts -X- _ O
and -X- _ O
require -X- _ O
frequent -X- _ O
visits -X- _ O
over -X- _ O
extended -X- _ O
periods -X- _ O
of -X- _ O
time. -X- _ O
Objective -X- _ O
Adjuvants -X- _ O
are -X- _ O
commonly -X- _ O
used -X- _ O
to -X- _ O
enhance -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
infectious -X- _ O
disease -X- _ O
vaccines -X- _ O
, -X- _ O
and -X- _ O
this -X- _ O
study -X- _ O
asked -X- _ O
whether -X- _ O
Advax -X- _ B-Intervention
( -X- _ I-Intervention
Vaxine -X- _ I-Intervention
Pty -X- _ I-Intervention
Ltd -X- _ I-Intervention
, -X- _ I-Intervention
Adelaide -X- _ I-Intervention
, -X- _ I-Intervention
Australia -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
a -X- _ O
novel -X- _ O
noninflammatory -X- _ O
polysaccharide -X- _ O
adjuvant -X- _ O
, -X- _ O
might -X- _ O
provide -X- _ O
similar -X- _ O
benefits -X- _ O
for -X- _ O
allergy -X- _ O
desensitization. -X- _ O
Methods -X- _ O
A -X- _ O
randomized -X- _ O
, -X- _ O
controlled -X- _ O
phase -X- _ O
1 -X- _ O
/ -X- _ O
2 -X- _ O
trial -X- _ O
was -X- _ O
undertaken -X- _ O
in -X- _ O
27 -X- _ B-Patient
adults -X- _ I-Patient
with -X- _ I-Patient
a -X- _ I-Patient
history -X- _ I-Patient
of -X- _ I-Patient
rapid-onset -X- _ I-Patient
systemic -X- _ I-Patient
allergic -X- _ I-Patient
reactions -X- _ I-Patient
to -X- _ I-Patient
honeybee -X- _ I-Patient
stings -X- _ I-Patient
and -X- _ I-Patient
positive -X- _ I-Patient
specific -X- _ I-Patient
IgE -X- _ I-Patient
levels -X- _ I-Patient
to -X- _ O
evaluate -X- _ O
the -X- _ O
safety -X- _ O
and -X- _ O
efficacy -X- _ O
of -X- _ O
honeybee -X- _ B-Intervention
venom -X- _ I-Intervention
immunotherapy -X- _ I-Intervention
( -X- _ I-Intervention
HBVIT -X- _ I-Intervention
) -X- _ I-Intervention
combined -X- _ I-Intervention
with -X- _ I-Intervention
Advax -X- _ I-Intervention
adjuvant. -X- _ I-Intervention
Venom -X- _ I-Intervention
immunotherapy -X- _ I-Intervention
( -X- _ I-Intervention
VIT -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
administered -X- _ O
monthly -X- _ O
for -X- _ O
30 -X- _ O
months -X- _ O
after -X- _ O
achievement -X- _ O
of -X- _ O
maintenance -X- _ O
doses. -X- _ O
Results -X- _ O
Advax-adjuvanted -X- _ B-Outcome
HBVIT -X- _ I-Outcome
was -X- _ I-Outcome
well -X- _ I-Outcome
tolerated. -X- _ I-Outcome
Around -X- _ I-Outcome
week -X- _ I-Outcome
14 -X- _ I-Outcome
of -X- _ I-Outcome
VIT -X- _ I-Outcome
, -X- _ I-Outcome
specific -X- _ I-Outcome
IgG4 -X- _ I-Outcome
responses -X- _ I-Outcome
peaked -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
groups -X- _ I-Outcome
but -X- _ I-Outcome
increased -X- _ I-Outcome
earlier -X- _ I-Outcome
, -X- _ I-Outcome
peaked -X- _ I-Outcome
higher -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
were -X- _ I-Outcome
better -X- _ I-Outcome
maintained -X- _ I-Outcome
through -X- _ I-Outcome
the -X- _ I-Outcome
end -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
study -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
Advax-adjuvanted -X- _ I-Outcome
arm. -X- _ I-Outcome
Several -X- _ I-Outcome
different -X- _ I-Outcome
patterns -X- _ I-Outcome
of -X- _ I-Outcome
serologic -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
VIT -X- _ I-Outcome
were -X- _ I-Outcome
seen -X- _ I-Outcome
; -X- _ I-Outcome
some -X- _ I-Outcome
subjects -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
dominant -X- _ I-Outcome
IgG4 -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
some -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
combined -X- _ I-Outcome
IgG4 -X- _ I-Outcome
and -X- _ I-Outcome
IgG1 -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
some -X- _ I-Outcome
had -X- _ I-Outcome
an -X- _ I-Outcome
exclusively -X- _ I-Outcome
IgG1 -X- _ I-Outcome
response. -X- _ I-Outcome
In -X- _ I-Outcome
some -X- _ I-Outcome
subjects -X- _ I-Outcome
specific -X- _ I-Outcome
IgE -X- _ I-Outcome
levels -X- _ I-Outcome
increased -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
induction -X- _ I-Outcome
phase -X- _ I-Outcome
and -X- _ I-Outcome
then -X- _ I-Outcome
decreased -X- _ I-Outcome
, -X- _ I-Outcome
whereas -X- _ I-Outcome
in -X- _ I-Outcome
others -X- _ I-Outcome
specific -X- _ I-Outcome
IgE -X- _ I-Outcome
levels -X- _ I-Outcome
progressively -X- _ I-Outcome
decreased -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
start -X- _ I-Outcome
of -X- _ I-Outcome
VIT. -X- _ I-Outcome
Conclusion -X- _ O
Advax -X- _ O
adjuvant -X- _ O
favorably -X- _ O
enhanced -X- _ O
the -X- _ O
immunogenicity -X- _ O
of -X- _ O
HBVIT -X- _ O
, -X- _ O
with -X- _ O
an -X- _ O
early -X- _ O
and -X- _ O
prolonged -X- _ O
switch -X- _ O
to -X- _ O
specific -X- _ O
IgG4 -X- _ O
production. -X- _ O
The -X- _ O
ability -X- _ O
of -X- _ O
Advax -X- _ O
adjuvant -X- _ O
to -X- _ O
enhance -X- _ O
VIT -X- _ O
efficacy -X- _ O
warrants -X- _ O
further -X- _ O
study -X- _ O
. -X- _ O

